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1933of the SCD equation because death did not actually occur.
Marathon race directors have adopted this approach (6), which
has had useful practical application in advising risk of participa-
tion, while assisting in event preparation and the best allocation of
limited resources.*Christine E. Lawless, MD, MBA
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Metoprolol,
But Which Metoprolol?
Effect on Inappropriate
Cardioverter-Deﬁbrillator TherapyRuwald et al. (1) studied the beneﬁt of carvedilol versus meto-
prolol for inappropriate antitachycardia pacing (ATP), using
data from the MADIT-CRT (Multicenter Automatic Deﬁ-
brillator Implantation with Cardiac Resynchronization Ther-
apy) trial. In a following editorial comment, Raitt (2) discusses
further the issue of inappropriate ATP. What is most surprising
is that neither Ruwald et al. (1) nor Raitt (2) specify metoprolol
as the tartrate or the succinate form. This failure to indicate
the rapid- or delayed-release forms of the medication whenconcluding superiority in favor of carvedilol has to be of concern
to the reader. The major clinical trial of metoprolol, MERIT-
HF (Metoprolol CR/XL Randomised Intervention Trial in
Congestive Heart Failure), which showed a signiﬁcantly decreased
all-cause mortality in their heart failure patients, speciﬁcally used
metoprolol succinate (3). When carvedilol and metoprolol were
compared in the COMET (Carvedilol or Metoprolol European
Trial) using metoprolol tartrate (target dose, 50 mg twice daily)
versus carvedilol (target dose, 25 mg twice daily), the composite
endpoint of mortality and all-cause admissions was not signiﬁ-
cantly different for the 2 medications, although the authors
considered that there was a suggestion of carvedilol superiority (4).
Obviously, the comparator in the current papers under consider-
ation (1,2) ideally should have been the succinate form of meto-
prolol, as in MERIT-HF (3).*Thomas F. Whayne, Jr, MD, PhD
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But Which Metoprolol?
Effect on Inappropriate
Cardioverter-Deﬁbrillator TherapyWe thank Dr. Whayne for the interest and questions that he had
with regard to our recently published results from the MADIT-
CRT (Multicenter Automatic Deﬁbrillator Implantation With
Cardiac Resynchronization Therapy) trial (1) and accompanying
editorial (2).
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1934In short, we found that carvedilol reduced the overall risk of
inappropriate implantable cardioverter-deﬁbrillator (ICD) ther-
apy by 36%, and speciﬁcally inappropriate ICD shock by 46%,
compared with metoprolol. Furthermore, we found that carve-
dilol reduced the risk of ICD therapy caused by atrial ﬁbrillation
by 50%. We agree with Dr. Whayne of the importance of
reporting which form of metoprolol was used (tartrate or succi-
nate) in our study. Unfortunately, we did not report this spe-
ciﬁcally in our report. However, a few months earlier, we
reported the overall effects of carvedilol and metoprolol in the
MADIT-CRT study on the endpoints of heart failure hospi-
talization or death and ventricular tachyarrhythmias (3). There
we found that carvedilol reduced the risk of these 2 endpoints
signiﬁcantly compared with metoprolol. In this paper, we pro-
vide a more detailed picture of the doses, the dose-response, and
the speciﬁc details on metoprolol succinate. In short, in the
MADIT-CRT trial, 88% of the patients on metoprolol were
taking the slow-release salt metoprolol succinate used in the
MERIT-HF (Metoprolol CR/XL Randomised Intervention
Trial in Congestive Heart Failure) trial (4). Results from both
study 1 (1) and study 2 (3) remained essentially the same, even if
patients on metoprolol tartrate were excluded from the analyses.
We agree with Dr. Whayne that for the present study (1), this
detail should not have been left out of the ﬁnal published ver-
sion, and we should have prioritized this speciﬁc information
more highly.*Martin H. Ruwald, MD, PhD
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